Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | EOS100850 + unspecified CTLA4 antibody |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| EOS100850 | EOS-100850|EOS 100850|Inupadenant | Adenosine Targeting 24 | EOS100850 is an antagonist that selectively targets the A2A receptor and inhibits downstream signaling, which potentially induces an inflammatory response against tumor cells (Cancer Res 2019;79(13 Suppl):Abstract nr 4147). | |
| unspecified CTLA4 antibody | experimental CTLA4 antibody | Immune Checkpoint Inhibitor 150 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|